Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuk-ALIVE: Low-dose IL-2 After Myocardial Infarction
NCT07610538Recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Mar 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of aldesleukin in myocardial infarction (MI) and coronary artery disease (CAD) (3 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Differences in tissue-resident Treg gene signature and Comparing tissue-resident Tregs to peripheral blood Tregs. Started Mar 2026; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
myocardial infarction (MI)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07610538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610538.